Abstract
Background
There is increasing awareness of nonerosive reflux disease (NERD) as a disease requiring treatment in Japan. This randomized, double-blind, placebo-controlled, parallel-group study was conducted to investigate the efficacy and safety of omeprazole 10 mg and 20 mg once daily in Japanese patients with NERD.
Methods
Patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break (grade M or N according to Hoshihara’s modification of the Los Angeles classification) were randomly assigned to one of three groups (omeprazole 10 mg or 20 mg, or placebo) once daily for 4 weeks.
Results
Overall, 355 patients were enrolled, of whom 284 were randomly assigned to one of the three groups (omeprazole 10 mg, n = 96; omeprazole 20 mg, n = 93; placebo, n = 95). The rate of complete resolution of heartburn in week 4 was significantly higher in patients treated with omeprazole 10 mg [32.3%, 95% confidence interval (CI), 22.9%–41.6%] or 20 mg (25.8%, 95% CI, 16.9%–34.7%) than in the placebo group (12.0%, 95% CI, 5.3%–18.6%). No significant difference between the two omeprazole groups was observed. The rate of complete resolution of heartburn by omeprazole was similar between patients with grade M and those with grade N esophagus. Omeprazole also increased the rate of sufficient relief from heartburn. Omeprazole was well tolerated.
Conclusions
Omeprazole 10 mg or 20 mg once daily is effective and well tolerated in patients with NERD regardless of their endoscopic classification.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fujiwara Y, Higuchi K, Watanabe Y, Shiba M, Watanabe T, Tominaga K, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol 2005;20:26–29.
Hoshihara Y. Endoscopic findings of GERD (in Japanese with English abstract). Nippon Rinsho (Jpn J Clin Med) 2004;62:1459–1464.
Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scandinavian J Gastroenterol 2005;40:1005–1009.
Okamoto K, Iwakiri R, Mori M, Hara M, Oda K, Danjo A, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 2003;48:2237–2241.
Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004;22:108–114.
Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998;30:19–27.
Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut 1999;44(Suppl 2):S1–S16.
Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974–979.
Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965–973.
Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119–124.
Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547–555.
Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, et al. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastrooesophageal reflux disease. Aliment Pharmacol Ther 2005;21(Suppl 2):10–18.
Armstrong D. Review article: gastric pH—the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004;20(Suppl 5):19–26.
Streets CG, DeMeester TR. Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol 2003;37:14–22.
Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808–1812.
De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594–598.
Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005;50:2009–2018.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:654–664.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–1479.
Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol 2005;11:4291–4299.
Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol 2006;41:554–561.
Amano Y, Ishimura N, Furuta K, Okita K, Masaharu M, Azumi T, et al. Interobserver agreement on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy 2006;38:1032–1035.
Ohkusa T, Maekawa T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther 2005;21:1331–1339.
Papa A, Urgesi R, Grillo A, Danese S, Guglielmo S, Reberto I, et al. Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD). Minerva Gastroenterol Dietol 2004;50:215–226.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–1920.
Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology 2006;130:1459–1465.
Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole. Digestion 1992;51(Suppl 1):93–101.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Uemura, N., Inokuchi, H., Serizawa, H. et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 43, 670–678 (2008). https://doi.org/10.1007/s00535-008-2214-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-008-2214-5